TCGA-56-8307-01A-11R-2296-07
— · cohortSQ1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ1
- subtype
- cohortSQ1
- age_years
- 55
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.500
- E2F_TARGETS+0.420
- G2M_CHECKPOINT+0.370
- MYC_TARGETS_V1+0.320
- INTERFERON_ALPHA_RESPONSE+0.300
- INTERFERON_GAMMA_RESPONSE+0.250
- ALLOGRAFT_REJECTION+0.210
- MITOTIC_SPINDLE+0.180
- KRAS_SIGNALING_DN+0.140
- APICAL_SURFACE+0.060
Top 10 suppressed
- COAGULATION-0.440
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.430
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.430
- GLYCOLYSIS-0.380
- HYPOXIA-0.370
- PROTEIN_SECRETION-0.370
- FATTY_ACID_METABOLISM-0.360
- CHOLESTEROL_HOMEOSTASIS-0.350
- MYOGENESIS-0.340
- NOTCH_SIGNALING-0.340
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1313149 | — | D | 0.907 |
| 2 | SRR1313128 | — | D | 0.877 |
| 3 | SRR11296816 | — | — | 0.859 |
| 4 | C3L-00603 | — | cohortSQ1 | 0.845 |
| 5 | SRR650176 | — | — | 0.841 |
| 6 | C3N-03080 | — | cohortSQ1 | 0.839 |
| 7 | NALM1_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE | CML | — | 0.839 |
| 8 | BV173_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE | CML | — | 0.836 |
| 9 | C3N-02728 | — | cohortMD1 | 0.835 |
| 10 | TCGA-96-A4JL-01A-11R-A24Z-07 | — | cohortSQ1 | 0.834 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 10 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.500 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.420 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.370 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.320 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.300 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.250 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.210 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.180 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.140 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.060 | Temsirolimus | — uncovered |